Month: June 2025

ATHENS, Greece, June 24, 2025 (GLOBE NEWSWIRE) — Performance Shipping Inc. (NASDAQ: PSHG), (“we” or the “Company”), a global shipping company specializing in the ownership of tanker vessels, today announced that it has accepted a commitment letter whereby it intends to enter into an agreement for a refinancing of the existing loan outstanding of US$29,750,000 with Alpha Bank A.E. (the “Facility”) through two separate wholly-owned subsidiaries of the Company. This Facility is subject to the completion of customary closing conditions and the execution of a final loan agreement by the Company and its lenders. Proceeds from the Facility will be used to refinance in full the existing indebtedness maintained with Alpha Bank and secured by the M/T P. Long Beach and the M/T P. Aliki. This Facility shall bear interest at the rate of SOFR...

WISe.ART Launches Mayte Spínola’s “Galactic Christ” into Space Aboard SpaceX Mission Pioneering Space-Based Art NFTs and Digital Expression  Geneva, Switzerland, June 24, 2025 –WISeKey International Holding Ltd (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, today announces that WISe.ART, its secure NFT marketplace subsidiary has successfully launched Spanish artist Mayte Spínola’s digital artwork El Cristo Cósmico (“The Galactic Christ”) into low Earth orbit (LEO) aboard a SpaceX Falcon 9 rocket, marking another milestone in the company’s strategy to expand the frontier of digital expression through space technology. The launch occurred at 23:11 CET on June 23, 2025, placing a WISeSat satellite carrying Spínola’s artwork into orbit. Tokenized as an NFT on the WISe.ART platform, the...

Vivoryon Therapeutics N.V. Reports Outcomeof 2025 Annual General Meeting Halle (Saale) / Munich, Germany, June 24, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on diabetic kidney disease, held its Annual General Meeting (AGM) today at 1:00 p.m. (CEST). The shareholders approved all items on the agenda of the meeting, including the appointment of Dr. Julia Neugebauer, COO of Vivoryon since May 2025, to the Company’s Board as executive director. The re-appointment of Dr. Frank Weber and Anne Doering as executive directors, as well as the re-appointment of Dr. Erich Platzer, Charlotte Lohmann, Dr. Claudia Riedl and Dr. Samir Shah as non-executive directors to the Company’s...

QuantGold Enables AI to Compute on Sensitive Data without Exposure – Backed by 120+ Encryption Patents and Already Deployed in 100+ Institutions Targeting an approximate US$400 Billion Market, QuantGold Offers Encrypted, Pay-Per-Use AI Compute to Unlock the Sovereign Data Economy for Governments and Enterprises KUALA LUMPUR, Malaysia, June 24, 2025 (GLOBE NEWSWIRE) — VCI Global Limited (NASDAQ: VCIG) (“VCI Global” or the “Company”), a diversified global holding company, today announced the official launch of the QuantGold Data Platform (“QuantGold”), a sovereign-grade AI infrastructure designed to enable computation on sensitive datasets without compromising data ownership or privacy. The launch represents a major step forward in building secure, compliant AI systems capable of unlocking value from previously inaccessible data. VCI...

SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) — LPL Financial LLC announced today that financial advisors Mike Trudeau, CFP®, Matt Merrick, Ben Ollila, CFP® and Ben Prchal have joined LPL Financial’s broker-dealer, Registered Investment Advisor (RIA) and custodial platforms, aligning with existing RIA firm Strategic Wealth Group. They reported serving approximately $220 million in advisory, brokerage and retirement plan assets* and join LPL from Thrivent Investment Management. Based just outside of Minneapolis in Lino Lakes, Minn., Trudeau, Merrick and Ollila began collaborating in 2009 and bring a combined three decades of financial industry experience to the practice. Prchal, who entered the financial industry in 2021, completes the team. Together, they take a take a holistic approach to helping their clients — most of whom are nearing...

SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) — Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or the “Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as a result of their 2025 annual Russell Index reconstitution. “We are very pleased to be included in the Russell 2000® and Russell 3000® Indexes, which we anticipate will increase the company’s visibility with investors and institutions,” said Claude Maraoui, Journey Medical’s...

EMERYVILLE, Calif., June 24, 2025 (GLOBE NEWSWIRE) — National Mortgage Insurance Corporation (National MI), the primary operating subsidiary of NMI Holdings, Inc. (NASDAQ: NMIH), announced today it has received three prestigious company culture awards. National MI is proud to be recognized as a Great Place To Work® in 2025 and has also earned a “Decade of Great” distinction for garnering the honor ten consecutive years. Additionally, the company was ranked No. 22 among Fortune magazine’s Best Workplaces in the Bay Area. “We’re delighted to once again be recognized by Great Place to Work and even more proud to reach the ‘Decade of Great’ milestone based on the consistent feedback of our employees,” said Adam Pollitzer, President & CEO of National MI. “At National MI, we aim to lead with impact and a clear organizational mission,...

Mr. Cline brings extensive commercial expertise to lead the transition of Xenon to a commercial-stage company with the anticipated launch of azetukalner across three potential indications VANCOUVER, British Columbia and BOSTON, June 24, 2025 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced the appointment of Darren Cline as Chief Commercial Officer and member of the Xenon senior executive team. In this role, Mr. Cline will lead commercial strategy and operations for the Company’s portfolio of product and development candidates, with initial focus on its lead Phase 3 candidate, azetukalner, and first potential launch in epilepsy. Azetukalner is currently...

Enrollment is now underway across multiple clinical sites, in partnership with Syneos Health VANCOUVER, Washington, June 24, 2025 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that the first patient has been dosed in the Company’s clinical trial evaluating the efficacy of leronlimab in patients with relapsed/refractory microsatellite stable colorectal cancer (“CRC”). In partnership with Syneos Health, the Company has engaged eight clinical sites and counting, and patient enrollment and processing efforts are underway. The lead principal investigator for the trial is Dr. Ben Weinberg, MD, from Georgetown University and the MedStar Health Alliance. According...